Previous Next Accountability Why the new pharma business model can be bad for research and development Abstract: A new report from Rep. Katie Porter has an illuminating case study on the value of antitrust in health care. Publication: Vox Date Published: January 29, 2021 Author(s): Dylan Scott View This Resource